SpaceX Plans Starship Program For In-Orbit Drug Research- Bloomberg News
ReutersJul 15, 2025 2:31 PM
July 15 (Reuters) -
SPACEX PLANS STARSHIP PROGRAM FOR IN-ORBIT DRUG RESEARCH- BLOOMBERG NEWS
SPACEX PLANS TO MAKE STARSHIP PROGRAM FOR IN-ORBIT DRUG RESEARCH OPERATIONAL ROUGHLY BY THE END OF THE DECADE- BLOOMBERG NEWS
Source text: https://bloom.bg/4lxaW5T
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Stablecoins — The New Era of Financial “Colonization” and the Last Bastion of Dollar Dominance
TradingKey - On May 20, the U.S. Senate passed preliminary procedural votes on the “Guidance and Establishment of a National Stablecoin Innovation Act” (commonly known as the Stablecoin “Genius Act”).TradingKey
16 minutes ago
Eurozone June Harmonised Inflation Commentary: Short-Term Profit Potential for Euro Bulls
TradingKey - On 17 July 2025, the Eurozone's June Harmonised Inflation data was released, aligning with market expectations. The headline HICP rose slightly from 1.9% in May to 2.0%, while core HICP remained steady at 2.3%.TradingKey
an hour ago
Is Now the Time to Invest in U.S. Stocks Amid Renewed Tariff Uncertainty?
TradingKey - On July 7, President Donald Trump posted letters addressed to 14 world leaders outlining his updated tariff strategy.TradingKey
2 hours ago
What Is the GENIUS Act, and Why Is Its Impact Comparable to a Bitcoin Spot ETF?
The GENIUS Act represents a groundbreaking federal regulatory framework for U.S. stablecoins, defining legal issuance standards, oversight responsibilities, consumer protections, and reserve requirements. While its primary objective is to advance U.S. financial interests, it will significantly shaTradingKey
Fri, May 30
Wells Fargo Q1 2025: Is it a Fragile Fortress or a Mispriced Revival
TradingKey - Wells Fargo's (WFC) Q1 2025 results present a paradox: resiliency without momentum. Net income on the surface was up 6% year-over-year at $4.9 billion, which is $1.39 a diluted share for a 16% EPS lift driven by forceful share repurchases.TradingKey
Thu, May 1
Tradingkey
